ConvaTec Group stock (GB00BD3VFW73): growth guidance and strategy in focus after latest trading update

ConvaTec Group has reaffirmed its 2026 growth ambitions and updated investors on trading momentum, margins and portfolio priorities. Earnings trends, guidance and US exposure are increasingly in focus for shareholders after the latest company statements.

ConvaTec Group has recently updated investors on its trading momentum, profitability and medium-term growth ambitions, including targets for 2026 and comments on first-quarter 2025 trends, according to company communications and regulatory filings such as its full-year 2024 results released on 03/06/2025 and subsequent trading statements in early 2026 ConvaTec Group as of 03/06/2025.

These updates included information on organic revenue growth, adjusted operating margins and the performance of its main business units, along with guidance for 2025 and medium-term expectations through 2026, as summarized in company presentations and management commentary made available to investors during March 2025 and reiterated in early 2026 ConvaTec Group as of 03/06/2025.

As of: 18.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: ConvaTec
• Sector/industry: Medical technology, wound care and continence care
• Headquarters/country: London, United Kingdom
• Core markets: Europe and North America, with a notable presence in the United States
• Key revenue drivers: Advanced wound care, ostomy care, continence and critical care, infusion care solutions
• Home exchange/listing venue: London Stock Exchange (ticker: CTEC)
• Trading currency: GBP

ConvaTec Group: core business model

ConvaTec Group focuses on medical products for chronic conditions and long-term care environments, with portfolios in advanced wound care, ostomy care, continence and critical care and infusion care. The company targets both hospital settings and community or homecare channels. Its primary customers include healthcare providers, payers and distributors across major developed markets. ConvaTec emphasizes recurring demand, as many of its products are required on an ongoing basis for chronic conditions.

The group’s advanced wound care division offers dressings and solutions intended to manage complex wounds and support healing in acute and chronic cases. These products are used in hospitals, outpatient clinics and home settings, often reimbursed by public or private systems. Ostomy care provides pouches and accessories for patients who have undergone colostomy, ileostomy or urostomy surgery. This business tends to generate stable, repeat purchases and is an important contributor to ConvaTec’s recurring revenue base.

Continence and critical care includes devices for urinary continence, bowel management and intensive care units, while infusion care supplies sets and related equipment used in subcutaneous infusion therapies. These segments serve both chronic disease management and acute care situations. The company has indicated in multiple investor documents that it is pursuing innovation and new product launches across these areas to support growth and defend share against global competitors in the medtech and wound care space ConvaTec Group as of 03/06/2025.

ConvaTec’s business model combines direct sales in key countries with distribution partners in smaller markets. In the United States and other large economies, the company works with group purchasing organizations, hospital networks and payers to secure contracts and reimbursement coverage. Management has highlighted the importance of maintaining consistent product quality and service levels to retain contracts and secure renewals, given the competitive tender environment in many healthcare systems.

Main revenue and product drivers for ConvaTec Group

According to its full-year 2024 results released on 03/06/2025, ConvaTec reported group revenue growth driven mainly by advanced wound care and infusion care, with contributions from new product introductions and geographic expansion ConvaTec Group as of 03/06/2025. The company also provided adjusted operating profit figures and margin trends for 2024 in the same release, noting the impact of cost efficiency programs and price dynamics.

Advanced wound care remains a strategic focus, with management pointing to innovation in dressings and digital support tools as a way to help clinicians manage complex wounds more effectively. The business benefits from demographic trends such as aging populations and rising incidence of diabetes-related complications in many markets. At the same time, hospitals and payers face budget constraints, which may pressure pricing and encourage the adoption of cost-effective solutions, requiring ConvaTec to balance innovation with affordability.

Ostomy care is another important revenue pillar, providing recurring sales due to the long-term nature of ostomy management for patients. ConvaTec offers a range of pouches, skin barriers and accessories designed to improve comfort and reduce skin complications. The company’s investor materials indicate that it is investing in product design and patient support programs to differentiate its offering and support loyalty among users and caregivers ConvaTec Group as of 03/06/2025.

Continence and critical care products, including catheters and incontinence solutions, contribute to revenue in both hospital and homecare settings. These products are often used daily or multiple times per week, generating recurring demand but also facing competition from other established medical device suppliers. Infusion care, including infusion sets and related components, serves chronic therapies such as insulin and immunoglobulin treatments. Management has previously highlighted growth opportunities in this segment where ConvaTec partners with pharmaceutical and biotech companies that provide drugs administered via infusion systems.

In guidance accompanying its 2024 results and reiterated in early 2026 trading comments, ConvaTec outlined expectations for continued organic revenue growth and further improvement in adjusted operating margins over the medium term, though exact numerical targets may vary and are subject to market conditions and regulatory developments ConvaTec Group as of 03/06/2025. The company also referenced its 2026 ambitions, including revenue growth and margin improvement, in its strategic presentations.

Industry trends and competitive position

ConvaTec operates in global medical technology markets that are influenced by demographic factors, healthcare policy, reimbursement structures and technological innovation. Advanced wound care and ostomy care are categories characterized by a mix of large multinational medtech companies and specialized players. Market growth is supported by aging populations, rising chronic disease prevalence and an emphasis on preventing complications that can lead to longer hospital stays, but the pace of growth varies by region and reimbursement environment.

The United States is one of ConvaTec’s key markets and an important reference point for investors, given the size of the US healthcare system and its influence on global medical technology trends. The company’s exposure to the US market provides access to a large base of hospitals, outpatient wound centers and home health providers, but it also introduces regulatory and reimbursement complexity. Shifts in US healthcare policy, changes in Medicare or private payer rules and evolving product coding can affect volume and pricing for wound and ostomy products.

ConvaTec’s competitive position is shaped by its product portfolio breadth, distribution reach and ability to secure contracts with major purchasing organizations. Investor materials indicate that the company is pursuing a strategy of strengthening its core categories, improving service levels and expanding selectively in high-growth areas such as advanced therapies and digital support tools ConvaTec Group as of 03/06/2025. At the same time, competitors are investing heavily in innovation, and pricing pressure remains a recurrent theme across healthcare systems, meaning that execution on cost control and differentiation is critical for sustaining margins.

Regulatory oversight by agencies such as the US Food and Drug Administration and European notified bodies under the Medical Device Regulation framework creates additional requirements for product development, manufacturing and post-market surveillance. ConvaTec must comply with evolving standards for clinical evidence, quality systems and reporting. While this increases complexity and costs, it can also raise barriers to entry for smaller competitors and reinforce the importance of established players with strong compliance infrastructures.

Why ConvaTec Group matters for US investors

For US-based investors, ConvaTec represents an example of a London-listed healthcare company with direct exposure to the US medical device and homecare markets. Revenue from the United States and other North American countries forms a meaningful part of the group’s sales mix, according to company disclosures in its annual reports and presentations, providing a link to trends in North American healthcare demand and reimbursement ConvaTec Group as of 03/06/2025.

Because ConvaTec’s shares trade on the London Stock Exchange in pounds sterling, US investors who access the stock via international brokerage platforms or over-the-counter instruments are exposed not only to operational performance but also to currency movements between the US dollar and the British pound. Earnings translated into US dollars may fluctuate due to exchange rate changes, independent of underlying local-currency trends in revenue and profit. This foreign-exchange dimension is a recurring consideration when US investors evaluate UK-listed healthcare companies.

ConvaTec’s focus on chronic care and long-term product usage aligns with structural themes such as aging populations, increasing chronic disease burdens and continued expansion of home-based and community-based care services. For investors seeking exposure to these themes outside purely US-listed medtech names, ConvaTec offers a perspective on how a European-headquartered company approaches global wound care and ostomy markets. However, the company’s performance remains influenced by local dynamics in European health systems as well as regulatory and reimbursement decisions in its various regions.

Conclusion

ConvaTec Group continues to position itself as a specialist in chronic care-focused medical products, with strategic emphasis on advanced wound care, ostomy care and infusion care. Recent company communications, including full-year 2024 results and guidance for the period through 2026, have highlighted management’s targets for organic growth and margin improvement, while acknowledging the influence of pricing dynamics, input cost inflation and regulatory requirements on profitability ConvaTec Group as of 03/06/2025. For US investors looking at international healthcare exposure, the company offers access to structural themes in wound and ostomy care, but it also introduces currency risk and regional policy considerations. As with any medtech stock, future performance will likely depend on execution in innovation, market access and cost control rather than on any single product or region.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.